Butler Molly, Palacios Mario Espinosa, Carr Christopher, Moore-Hill Debra, Vale Fernando L
Medical College of Georgia at Augusta University, Augusta, Georgia.
Department of Neurosurgery, Wellstar-Medical College of Georgia Health, Augusta, Georgia.
Epilepsia. 2025 Mar;66(3):768-775. doi: 10.1111/epi.18229. Epub 2024 Dec 16.
Studies have shown that a growing number of people with epilepsy belong to minority groups and experience health disparities. Inclusivity in clinical trial enrollment is essential for advancing health access but has not been well studied among epilepsy trials. The objective of this study was to analyze US epilepsy clinical trials to identify the prevalence and trends associated with race and sex enrollment disparities.
We queried the Clinicaltrials.gov registry to identify completed epilepsy clinical trials with results reported between 2006 and 2022. Studies were assessed for reporting of participant race and sex information, and measures of trial diversity including the participation to prevalence ratio (PPR), representation ratio (RR), and representation quotient (RQ) were calculated. Other data including funding source, intervention type, location, and trial dates were also extracted.
Ninety trials met inclusion criteria, of which 89 (99%) and 53 (59%) reported participant sex and race, respectively. Three trials included only female participants and were excluded from further sex-specific analyses. Females were underrepresented in 10 of the remaining 86 trials reporting sex information (PPR < .8, 12%). We found that industry-funded trials were more likely to have equal female representation among participants (p = .0197). Of trials reporting participant race, 52 (98%) exhibited a lack of racial diversity (RQ < 1). Black participants were the most frequently underrepresented racial group (RR < 1, 42 of 53 trials, 79%).
Our findings highlight significant disparities in epilepsy clinical trial enrollment, particularly for Black participants. Lack of diversity and underrepresentation of historically marginalized populations may contribute to research biases and perpetuate health inequities. More inclusive research practices are needed to ensure all people with epilepsy have access to effective care.
研究表明,癫痫患者中属于少数群体且存在健康差异的人数日益增多。临床试验入组的包容性对于改善医疗可及性至关重要,但在癫痫试验中尚未得到充分研究。本研究的目的是分析美国癫痫临床试验,以确定与种族和性别入组差异相关的患病率及趋势。
我们查询了Clinicaltrials.gov登记处,以确定2006年至2022年期间报告结果的已完成癫痫临床试验。评估研究中参与者种族和性别信息的报告情况,并计算试验多样性指标,包括参与率与患病率之比(PPR)、代表性比率(RR)和代表性商数(RQ)。还提取了其他数据,包括资金来源、干预类型、地点和试验日期。
90项试验符合纳入标准,其中89项(99%)和53项(59%)分别报告了参与者的性别和种族。3项试验仅纳入女性参与者,被排除在进一步的性别特异性分析之外。在其余86项报告性别信息的试验中,有10项试验女性代表性不足(PPR<.8,12%)。我们发现,由行业资助的试验中参与者的女性代表性更可能相等(p = 0.0197)。在报告参与者种族的试验中,52项(98%)缺乏种族多样性(RQ<1)。黑人参与者是代表性最不足的种族群体(RR<1,53项试验中有42项,79%)。
我们的研究结果突出了癫痫临床试验入组方面的显著差异,尤其是黑人参与者。缺乏多样性以及历史上被边缘化人群代表性不足可能导致研究偏差,并使健康不平等长期存在。需要更具包容性的研究实践,以确保所有癫痫患者都能获得有效的治疗。